BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26732020)

  • 21. TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.
    Oh EJ; Lee S; Bae JS; Kim Y; Jeon S; Jung CK
    Endocr Pathol; 2017 Mar; 28(1):49-53. PubMed ID: 27688081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.
    George JR; Henderson YC; Williams MD; Roberts DB; Hei H; Lai SY; Clayman GL
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1550-9. PubMed ID: 26461266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.
    Su X; Jiang X; Wang W; Wang H; Xu X; Lin A; Teng X; Wu H; Teng L
    Onco Targets Ther; 2016; 9():6965-6976. PubMed ID: 27956840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.
    Shi H; Guo LH; Zhang YF; Fu HJ; Zheng JY; Wang HX; Zhao CK; Xu HX
    Endocrine; 2020 May; 68(2):349-357. PubMed ID: 32026251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
    Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
    Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
    Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
    Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years.
    Hu Y; Xu S; Dong L; Pan Z; Zhang L; Zhan W
    Front Endocrinol (Lausanne); 2024; 15():1322731. PubMed ID: 38562417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations of the
    Liu R; Li Y; Chen W; Cong J; Zhang Z; Ma L; Chu L; Xiao H; Zhang Y; Liu Y; Xu Y; Yu Q; Yang X; Sun C
    Oncol Lett; 2020 Oct; 20(4):50. PubMed ID: 32802170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
    Jin A; Xu J; Wang Y
    Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
    Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
    Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
    Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients.
    Yang H; Park H; Ryu HJ; Heo J; Kim JS; Oh YL; Choe JH; Kim JH; Kim JS; Jang HW; Kim TH; Kim SW; Chung JH
    Endocrinol Metab (Seoul); 2022 Aug; 37(4):652-663. PubMed ID: 35864728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma.
    Hirokawa T; Arimasu Y; Chiba T; Fujiwara M; Kamma H
    Pathol Int; 2020 Apr; 70(4):217-223. PubMed ID: 31943527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.
    Wang Z; Chen JQ; Liu JL; Qin XG
    Eur J Clin Invest; 2016 Feb; 46(2):146-57. PubMed ID: 26648183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
    Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
    Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.